Beyond Air's Subsidiary Beyond Cancer Announces Early Signs Of Clinical Activity And Safety And Tolerability Profile From Phase 1 Clinical Trial Evaluating Single Intratumoral UNO Injection Administered As Monotherapy

Beyond Cancer, Ltd., a subsidiary of Beyond Air, Inc. (NASDAQ: XAIR), reported early signs of clinical activity and a favorable safety profile from its Phase 1 trial evaluating a single intratumoral injection of ultra-high concentration nitric oxide (UNO) as a monotherapy for solid tumors. The trial included ten heavily pretreated patients, with seven remaining alive 19 to 37 months post-treatment, and two patients with triple negative breast cancer showing no evidence of disease. The treatment was generally well-tolerated, with most adverse events classified as Grade 1, and one serious event (hypoxia) that resolved fully.